Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results
June 14, 2022 16:01 ET
|
Rafael Holdings, Inc.
NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for...
Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results
March 17, 2022 16:01 ET
|
Rafael Holdings, Inc.
NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for...
William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022
January 21, 2022 07:00 ET
|
Rafael Holdings, Inc.
NEWARK, N.J., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), a company focused on discovering and developing novel cancer and immune metabolism therapeuties through its Barer...
Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results
December 15, 2021 16:30 ET
|
Rafael Holdings, Inc.
NEWARK, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage cancer and immune metabolism therapeutics company, today reported its financial results for the...
Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus
November 22, 2021 07:00 ET
|
Rafael Holdings, Inc.
- Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Company’s Board of Directors and Chair Newly Established Transition Committee - ...
Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia
October 28, 2021 07:00 ET
|
Rafael Holdings, Inc.
Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in...
Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
October 18, 2021 17:30 ET
|
Rafael Holdings, Inc.
NEWARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), announced that today it made a grant to Dr. Mary Margaret Huizinga of options to purchase 122,341 shares of Class...
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update
October 18, 2021 16:30 ET
|
Rafael Holdings, Inc.
We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year We expect to submit our...